September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Changes in the sarcoglycan complex and effects of (-)-epicatechin in SGCD-null mice as a potential animal model for retinal degeneration
Author Affiliations & Notes
  • Andric Christopher Perez-Ortiz
    Laboratory of Molecular Biology, Universidad Panamericana School of Medicine, Benito Juarez, Distrito Federal, Mexico
  • Gabriela Solano-García
    Department of Neuroscience, Instituto Nacional de Rehabilitación, Distrito Federal, Mexico
  • Alexandra Luna-Angulo
    Department of Neuroscience, Instituto Nacional de Rehabilitación, Distrito Federal, Mexico
  • Ramon M Coral-Vazquez
    Escuela Superior de Medicina, Instituto Politécnico Nacional, Distrito Federal, Mexico
  • Yonathan Garfias
    Instituto de Oftalmologia F.A.P. Conde de Valenciana, I.A.P., Distrito Federal, Mexico
  • Viridiana Garcia-Perez
    Centro médico nacional 20 de noviembre, ISSSTE, Distrito Federal, Mexico
  • Sergio De los Santos-Enriquez
    Centro médico nacional 20 de noviembre, ISSSTE, Distrito Federal, Mexico
  • Alvaro Rendon
    Institut de la Vision, Paris, France
  • Israel Ramirez-Sanchez
    Laboratory of Molecular Biology, Universidad Panamericana School of Medicine, Benito Juarez, Distrito Federal, Mexico
  • Francisco Javier Estrada-Mena
    Laboratory of Molecular Biology, Universidad Panamericana School of Medicine, Benito Juarez, Distrito Federal, Mexico
  • Footnotes
    Commercial Relationships   Andric Perez-Ortiz, None; Gabriela Solano-García, None; Alexandra Luna-Angulo, None; Ramon Coral-Vazquez, None; Yonathan Garfias, None; Viridiana Garcia-Perez, None; Sergio De los Santos-Enriquez, None; Alvaro Rendon, None; Israel Ramirez-Sanchez, None; Francisco Estrada-Mena, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 1732. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Andric Christopher Perez-Ortiz, Gabriela Solano-García, Alexandra Luna-Angulo, Ramon M Coral-Vazquez, Yonathan Garfias, Viridiana Garcia-Perez, Sergio De los Santos-Enriquez, Alvaro Rendon, Israel Ramirez-Sanchez, Francisco Javier Estrada-Mena; Changes in the sarcoglycan complex and effects of (-)-epicatechin in SGCD-null mice as a potential animal model for retinal degeneration. Invest. Ophthalmol. Vis. Sci. 2016;57(12):1732.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Molecular underpinnings of retinal degeneration (RD) are poorly understood, there is an increasing need of therapeutic molecules to revert or prevent further damage in patients. The aim of this work is to investigate the changes in expression of the sarcoglycan complex (SGC) in a delta-sarcoglycan (SGCD) null mice as a potential model for RD. We also tested the effects of (-)-epicatechin as a treatment option.

Methods : Sixteen C57BL/6J sgcd-/- mice and 12 C57BL/6J wild type (WT) mice were equally divided into two groups. All animals were 3 months old and were handled according to the ARVO Statement for the use of animals in Ophthalmic and Visual Research. Intervention group received 1mg/kg/day of (-)-epicatechin q12h PO diluted in DMSO 2% for 14 days. After enucleation, mice eyes were fixed for 1hr in 4% paraformaldehyde and dehydrated in a sucrose gradient (10-30%). Eyes were cryoprotected before embedding in freezing medium and frozen in liquid nitrogen. Sagittal cross-sections were cut at 10 μm. We performed indirect immunofluorescence (IF) for beta-, gamma-, delta-, and epsilon-sarcoglycans. Also, hematoxylin-eosin (H&E) staining on the tissues was performed.

Results : We compared WT against SGCD-null mice in regards of retinal architecture by means of H&E staining. In figure 1, we observe that all layers appear frailer. Also, there is a notably decrease on the thickness in the inner plexiform layer (IPL). After treatment, SGCD null mice show a discrete increase in thickness in the IPL and the cross-sections appear more firm. Overall, SGC IF staining exhibits an up-regulation after (-)-epicatechin treatment in both WT and null.

Conclusions : Taken together all the results we suggest that SGCD null mice is a model of RD. Furthermore, we propose the (-)-epicatechin regimen as a possible treatment for RD as it can re-establish in part the retinal architecture in this model. Also, there are several changes in distribution and expression of the SGC proteins in the retina of SGCD (-/-) mice.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

Figure 1. H&E staining. Comparison between wild type (A), SGCD null treated with DMSO (B), and SGCD null mice treated with (-)-epicatechin. Arrows show areas of retinal fragility.

Figure 1. H&E staining. Comparison between wild type (A), SGCD null treated with DMSO (B), and SGCD null mice treated with (-)-epicatechin. Arrows show areas of retinal fragility.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×